| Autor: |
Blanca Norero, Gonzalo Latorre, Diego Reyes, Carlos Benitez, Rodrigo Wolff, Marco Arrese, Macarena Viñuela Morales, Matias Torres Parada, Gabriel Mezzano, Herman Aguirre, Javiera Busquets, Edmundo Martinez, Maria Elisa Tapia, Natalia Mendoza, Claudia Pavez, Alexandra Ginesta, Fernando Gomez, Jorge Contreras, Edgar Sanhueza, Monserrat Rius, Andrea Jimenez, Lorena Castro, Javier Brahm, Guillemo Silva, Alvaro Urzua, Jaime Poniachick, Edith Contreras, José Miguel Leiva, Edmundo Aravena, Macarena Larrain, Nicolás Lama, Olga Barajas, Alejandro Ferrada, Pauline Herman, Pamela Yaquich, Raúl Lazarte, Rodrigo Zapata |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 28, Iss , Pp 100936- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2023.100936 |
| Popis: |
Introduction and Objectives: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Still, there are epidemiological and clinical data in Latin America. In Chile, this is the first study regarding HCC with a significant number of patients. This study aimed to obtain and analyze clinical and epidemiological data of Chilean patients with HCC. Materials and Methods: Multicenter study from 12 Chilean hospitals that have members of the Chilean Association of Hepatology as members of their staff. Clinical records from 2015-2021 were included. Kaplan-Meier survival curves and Cox regression analysis were obtained. Results: We obtained data from 856 patients with HCC from 12 different centers. Median age 67 years old; 58.7% male. Cirrhosis is present in 91.2% (779) of cases. Main risk factors reported: fatty liver 47.9%(410), alcohol 19.6% (68), viral 12.2%(104) and autoimmune 3.5% (30). The median MELD score was 11.7 (CI95% 11,4-12). 38% (322) were diagnosed during surveillance; this was associated with earlier BCLC stage (OR 2,6; CI95%1,9-3,4). BCLC stages at diagnosis were 0; 8,2%(69), A: 38,5%(326), B:29,9%(253), C: 15,4%(130) and D: 8,2%(69). The main initial treatments were TACE, ablation, resection, liver transplant and sorafenib in 27,4%(226), 19,3%(159), 11,4%(94), 8%(66) and 5,5%(45), respectively. 53,4%(452) pts were in Milan Criteria at diagnosis. 9,1%(78) patients got a liver transplant. Five-year survival was 24% (CI95%20-28). The main factors associated with survival are depicted in Figure 1. Conclusions: Fatty liver was remarkably the main risk factor reported for HCC in our Chilean cohort. This is a worrisome number since NAFLD is on the rise worldwide, and especially in Latin America. Surveillance is key for early detection. The liver function defined by Child-Pugh and HCC stage using BCLC staging is strongly associated with survival. Liver transplant is still a scarce treatment resource. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
